A therapeutic approach towards microRNA29 family in vascular diabetic complications: A boon or curse?
- 1 June 2019
- journal article
- review article
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 18 (1) , 243-254
Abstract
Diabetes Mellitus (DM) is one of the major metabolic disorders and its severity leads to death. Enhancement in hyperglycaemic conditions of DM gives rise to endothelial impairment in small and large blood vessels contributing towards microvascular and macrovascular complications respectively. The pathogenesis of diabetic complications is associated with interruption of various signal transduction pathways due to epigenetic modifications such as aberrant histone modifications, DNA methylation and expression of miRNAs along with the long non-coding RNAs (lncRNAs). Amongst these epigenetic alterations, modulated expressions of miRNAs confer to apoptosis and endothelial dysfunction of organs that gives rise to vascular complications. In this review, we principally focussed on physiological role of miR29 family in DM and have discussed crosstalk between miR29 family and numerous genes involved in signal transduction pathways of Diabetic vascular complications. Incidences of diabetic retinopathy exploiting the role of miR29 in regulation of EMT process, differential expression patterns of miR29 and promising therapeutic role of miR29 have been discussed. We have summarised the therapeutic role of miR29 in podocyte impairment and how miR29 regulates the expressions of profibrotic, inflammatory and ECM encoding genes in renal fibrosis under diabetic conditions. We have also highlighted impact of miR29 expression patterns in cardiac angiopathy, cardiomyocyte's apoptosis and cardiac fibrosis. Additionally, we have also presented the contradictory actions of miR29 family in amelioration as well as in enhancement of diabetic complications.Keywords
This publication has 100 references indexed in Scilit:
- The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injuryPhysiological Genomics, 2012
- miR-29a and miR-29b Contribute to Pancreatic β-Cell-Specific Silencing of Monocarboxylate Transporter 1 (Mct1)Molecular and Cellular Biology, 2011
- Class IIa Histone Deacetylases Are Hormone-Activated Regulators of FOXO and Mammalian Glucose HomeostasisCell, 2011
- MicroRNA-29c Is a Signature MicroRNA under High Glucose Conditions That Targets Sprouty Homolog 1, and Its in Vivo Knockdown Prevents Progression of Diabetic NephropathyJournal of Biological Chemistry, 2011
- The Promise of MicroRNA Replacement TherapyCancer Research, 2010
- Transcriptional suppression of mir‐29b‐1/mir‐29a promoter by c‐Myc, hedgehog, and NF‐kappaBJournal of Cellular Biochemistry, 2010
- Renal Medullary MicroRNAs in Dahl Salt-Sensitive RatsHypertension, 2010
- MicroRNA: a new frontier in kidney and blood pressure researchAmerican Journal of Physiology-Renal Physiology, 2009
- Obesity and genetics regulate microRNAs in islets, liver, and adipose of diabetic miceMammalian Genome, 2009
- MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3BProceedings of the National Academy of Sciences, 2007